This Article Full Text Full Text (PDF) Supplemental Data Submit a related Letter to the Editor View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tham, E. Articles by Nordenskjöld, M. Search for Related Content PubMed PubMed Citation Articles by Tham, E. Articles by Nordenskjöld, M. Related Collections Neuroendocrinology and Pituitary Calcium and Bone Metabolism Endocrine Oncology Metabolism

Clinical Testing for Mutations in the MEN1 Gene in Sweden: A Report on 200 Unrelated Cases

Department of Molecular Medicine and Surgery (E.T., M.N.), Karolinska Institutet, 171 76 Stockholm, Sweden; Department of Clinical Genetics (U.G.), Karolinska University Hospital Solna, 171 76 Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes (E.L.), Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden; Department of Medicine (G.T.), Section of Endocrinology, University Hospital, 581 83 Linköping, Sweden; and Department of Medical Sciences (B.S.), Uppsala University, Uppsala University Hospital, 75185 Uppsala, Sweden

Address all correspondence and requests for reprints to: Emma Tham, Department of Molecular Medicine and Surgery, Center of Molecular Medicine L8:02, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden. E-mail: emma.tham{at}karolinska.se.

Context: Multiple endocrine neoplasia type 1 (MEN1) is a tumor syndrome of the parathyroid, endocrine pancreas, and anterior pituitary caused by mutations in the MEN1 gene on 11q13.

Objective: The goal of this study was to determine the MEN1 mutation spectrum and detection rate among Swedish patients and identify which patient categories should be tested for MEN1 mutations.

Design/Setting/Patients: DNA sequences and referral forms from patients referred to the Department of Clinical Genetics at Karolinska University Hospital, Sweden, for clinical MEN1 mutation screening were analyzed. The mutation status of 371 patients (including 200 probands) was ascertained, and the multiplex ligation-dependent probe amplification (MLPA) assay was evaluated for the detection of large deletions.

Main Outcome Measure: The main outcome measure was MEN1 genotypes.

Results: Forty-eight of 200 index cases (24%) shared 40 different mutations (18 novel). A total of 69% of all mutations resulted in a truncated protein. Two large deletions were detected by MLPA. A total of 94% of all MEN1 families had a mutation in the coding region of the MEN1 gene. A total of 6% of sporadic cases had MEN1 mutations. There was no correlation between severe disease and mutation type or location.

Conclusions: A total of 4% of all mutations were large deletions, and MLPA is now included in our standard MEN1 mutation screening. Individuals with at least one typical endocrine tumour and at least one of the following: 1) a first-degree relative with a major endocrine tumor; 2) an age of onset less than 30 yr; and/or 3) multiple pancreatic tumors/parathyroid hyperplasia were most likely to harbor a mutation; thus these patients should be screened for MEN1 mutations.

This article has been cited by other articles:

				A. Falchetti and M. L. Brandi Multiple Endocrine Neoplasia Type I Variants and Phenocopies: More than a Nosological Issue? J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1518 - 1520. [Full Text] [PDF]

				D M Lourenco Jr, R A Toledo, I I Mackowiak, F L Coutinho, M G Cavalcanti, J E M Correia-Deur, F Montenegro, S A C Siqueira, L C Margarido, M C Machado, et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile Eur. J. Endocrinol., September 1, 2008; 159(3): 259 - 274. [Abstract] [Full Text] [PDF]

eLetters: